Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2020 and 2021.
-
Tight liquidity NBB
Cash and receivables cover 18 % of short-term debt in 2021; threshold 65 %.
-
Busy address KBO
17 other companies have their registered office at the same address; threshold 10.
-
Legal situation KBO
Opening faillissement according to the CBE.
Financials
Financial year 2021
EXTENSE PHARMA from Wavre, company number BE0821673538, closed financial year 2021 with a result of € -120,752 after tax. For that financial year EXTENSE PHARMA recorded a gross margin of € -42,955 and equity of € -437,008. Compared with financial year 2020, the result moved from € -61,973 to € -120,752. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 24, 2022.
€ -437,008
▼ € 120,752 vs 2020
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -120,752
▼ 95 % more loss than in 2020
Profit after tax over the fiscal year.
€ 83
▼ 86% vs 2020
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -605,608.
Debts at end 2021
€ 468,240
▲ 23% vs 2020
€ 164,707 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 116,803
▼ 23% vs 2020
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2020 | 2021 | Change 2020 → 2021 | |
|---|---|---|---|
| Gross margin | € 19,652 | € -42,955 | ▼ € 62,607 |
| Profit after taxes | € -61,973 | € -120,752 | ▼ € 58,780 |
| Equity | € -316,256 | € -437,008 | ▼ € 120,752 |
| Total debts | € 772,266 | € 831,224 | ▲ 8% |
| Cash | € 603 | € 83 | ▼ 86% |
| Retained profit | € -484,856 | € -605,608 | ▼ € 120,752 |
| Bank debt | € 380,793 | € 468,240 | ▲ 23% |
| Balance sheet total | € 456,010 | € 394,215 | ▼ 14% |
Key figures of EXTENSE PHARMA, fiscal years 2020 to 2021, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2022 has not been filed yet; it was expected before 31 July 2023.
What happened to EXTENSE PHARMA?
What happened at EXTENSE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
EXTENSE PHARMA is active according to the CBE. Legal situation: Opening faillissement.
- New annual accounts for financial year 2021: loss of € 120,752. filed late Source: NBB ↗
- New establishment in Lasne. KBO
- Christel WULLAERT became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 61,973 loss in 2020 to € 120,752 loss in 2021.
Paid € 795 in corporate taxes since 2020.
A new publication or filing at EXTENSE PHARMA? We notify you, reason included.
Follow EXTENSE PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind EXTENSE PHARMA is Christel WULLAERT.
Directors
According to the 2021 annual accounts
Christel WULLAERT
Manager
since 2009
Establishments
Establishment units
Physical locations of this company
Rue Charles Jaumotte 29-31
1300 Wavre
Avenue Vendôme 1
1380 Lasne
Active since 1 January 2010
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 17 companies are registered at this address.
All companies at this address →L' OFFICE DU PRET HYPOTHECAIRE
€ 103,228 gross margin · 2022
OFFICE DU PRET HYPOTHECAIRE DE Belgique
€ 23,609 gross margin · 2022
GROUPE THIBAULT GROEP
€ -1,851 gross margin · 2025
ODPH HAINAUT
EQUINOXIAL
€ 6,690 gross margin · 2025
+12 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0821.673.538
- VAT number
- BE 0821.673.538
- Registered office
- Rue Charles Jaumotte 29-31, 1300 Wavre
- Names & denominations
- EXTENSE PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Opening faillissement
- Start date
- 17 December 2009
- Peppol
- Not registered
- Activities · NACE
Handelsbemiddeling in de groothandel in andere specifieke goederen
Vervaardiging van gehomogeniseerde voedingspreparaten en dieetvoeding